MENU
RemediumOne along with Washington University in St. Louis and The George Institute for Global Health supported the development and evaluation of an innovative HFrEF polypill-based implementation strategy to enhance guideline-directed medical therapy for patients with heart failure with reduced ejection fraction (HFrEF).
Guideline-directed medical therapy (GDMT) for HFrEF typically involves combining multiple medications—such as beta-blockers, ACE inhibitors/ARBs/ARNIs, and SGLT2 inhibitors. However, “pill burden” and complex regimens often lead to poor patient adherence, which is a major barrier to optimal outcomes. The pilot study addresses this critical challenge through an innovative polypill-based implementation strategy. By combining essential GDMT medications into a single, fixed-dose pill, this strategy aims to dramatically simplify treatment, enhance adherence, and systematically improve the delivery of evidence-based care for patients in diverse healthcare settings.
The pilot study was conducted at two tertiary care hospitals in Sri Lanka, National Hospital of Sri Lanka and Colombo South Teaching Hospital. The study successfully recruited 40 patients from both inpatient and outpatient settings.
The pilot trial results, confirming the feasibility of the study design, were recently presented by Prof. Anubha Agarwal, Chief Executive Officer, The George Institute for Global Health at the CVCT – Cardiovascular Clinical Trialists Forum.
Building on these findings, a randomized controlled trial is planned to start this year across 13 trial centres in Sri Lanka, to evaluate the impact of the HFrEF polypill on key cardiovascular outcomes.
Through such initiatives, RemediumOne continues to advance evidence-based heart failure care and improve patient outcomes.
